Imaging Study Using a PET Scan Agent in Blood and Histiocytic Cancers
Tests a PET imaging agent, pentixafor, to see it in lymphoma, myeloma, or histiocytic disorders.
Plain-language title generated from the registry record
Registry title: In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Early phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with blood cancers such as non-Hodgkin lymphoma, multiple myeloma (or its early forms MGUS/SMM) or histiocytic neoplasms, and also some solid tumors. They will have a [68Ga]-pentixafor PET/CT scan.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Proven blood cancer, either never treated, not responding to treatment, or relapsed. Includes indolent B- or T-cell non-Hodgkin lymphoma or mantle cell lymphoma with measurable disease; histiocytic neoplasms (LCH, ECD, RDD); MGUS, SMM or multiple myeloma; and solid tumors such as lung cancer, meningioma or adrenocortical tumors.
Main reasons for not taking part
- Breast-feeding
- Chronic kidney disease with eGFR<30
- Refusing or unable to tolerate the scan (for example, due to claustrophobia)
- Positive pregnancy test for women who could become pregnant
Read by machine on 9 November 2026.
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT05093335
- Record updated
- 5 February 2026
- Original description
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).Read full original descriptionShow less
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Inclusion: Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:; Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria; or; Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD); MGUS/SMM or MM according to IMWG definitions; Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease; Age ≥18; Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained <2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention; MSKCC patients.
Exclusion: History of renal functional disorders (chronic kidney disease with eGFR<30); Breast-feeding; Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia).